Filana Therapeutics (FLNA) Debt by Year
Filana Therapeutics, Inc. held $95.5M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Filana Therapeutics, Inc. has filed alongside them.
Ticker history: SAVA became FLNA (Filana Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View SAVA history.
Annual figures, oldest first. Point at a bar to read its period.
FLNA Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing | FY16Filing | FY15Filing | FY14Filing | FY13Filing | FY12Filing | FY11Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $95.5M-25.7% | $128.6M+6.1% | $121.1M-39.7% | $201.0M-13.9% | $233.4M+149.6% | $93.5M+305.1% | $23.1M+16.5% | $19.8M+89.0% | $10.5M-36.9% | $16.6M-46.9% | $31.3M-22.9% | $40.6M-16.5% | $48.6M-1.6% | $49.4M-32.5% | $73.1M |
FLNA Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'25Filing | Q1'2510-Q | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $82.7M-26.4% | $86.6M-26.2% | $95.5M-25.7% | $106.1M-28.8% | $112.4M-45.8% | $117.3M-5.5% | $128.6M+6.1% | $149.0M+4.7% | $207.3M+23.1% | $124.2M-33.8% | $121.1M-39.7% | $142.3M-18.5% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Filana Therapeutics, Inc. financials
Frequently Asked Questions
Filana Therapeutics, Inc. held $95.5M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Filana Therapeutics, Inc. (FLNA) reported on that line in every period on record.